BMRA_OUT_1 [2025-04-17 19:17:08 -0400] 4175 Bytes | 1072 tokens | Cum: 1072 tkns (13.40% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 7:17 PM on Thu Apr 17, 2025, and I'm firing up the spotlight on BIOMERICA (BMRA), moving from $0.4201 to $0.5099. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

--- COMPANY PROFILE ---
Company: BIOMERICA (BMRA)
IPO: 1978-09-26 (46 Years Ago)
Market Cap: $10,140,358
Shares Outstanding: 20,370,000
Industry: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Exchange: XNAS
Description: Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.

Here’s a list of headlines for BIOMERICA:

Today 08:19AM - United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel Kidney Disease Test for Early Detection of Kidney Damage
Apr-16-25 09:00AM - Biomerica Announces Reverse Stock Split
Apr-15-25 08:19AM - Biomerica Reports Third Quarter Fiscal 2025 Financial Results
Feb-27-25 05:18AM - Biomericas tests for IBD conditions gain CE-marking under EUs IVDR
Feb-26-25 08:19AM - Biomerica Achieves IVDR Certification in the European Union for Food Intolerance Tests Targeting Crohn's Disease and Ulcerative Colitis
Feb-19-25 08:19AM - Biomerica's inFoods IBS Clinical Trial Results Published and Featured in Gastroenterology, the Leading GI Medical Journal
Jan-17-25 10:48AM - Biomericas prostate cancer detection test gains approval from MOHAP
Jan-16-25 08:19AM - United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel PSA Screening Test to Detect an Early Sign of Prostate Cancer

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-12-10T14:09:52Z - Injection Molding Market to Reach USD 418.39 Billion By 2031 | SkyQuest Technology
B2 - 2024-08-29T13:00:00Z - Biomerica Reports Fiscal 2024 Year End Results
B3 - 2024-07-01T11:47:00Z - Biomerica Launches At-Home Sample Collection for inFoods® IBS, Significantly Expanding Access for Millions of IBS Sufferers
B4 - 2024-05-13T12:19:00Z - Biomerica Announces inFoods® IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024
B5 - 2024-04-29T12:19:00Z - Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement
B6 - 2024-04-15T11:47:00Z - Biomerica provides update on inFoods® IBS expansion

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for BIOMERICA (BMRA).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

BMRA_OUT_3 [2025-04-17 19:17:10 -0400] 856 Bytes | 231 tokens | Cum: 1305 tkns (16.31% of 8k)
==========================================================================

Showing B2 (chunk 1 of 1): B2:
**Biomerica Reports Fiscal 2024 Year End Results**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/08/29/2937803/0/en/Biomerica-Reports-Fiscal-2024-Year-End-Results.htmlBiomerica reported a modest 1% increase in total revenue for fiscal year 2024, with a 5% increase in core revenue excluding COVID-19 tests. The company implemented a significant cost-savings plan and reduced its net loss by 15%. Key milestones included FDA clearance for its Hp Detect Stool Antigen ELISA test and progress in the inFoods IBS pilot program.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BMRA_OUT_5 [2025-04-17 19:17:11 -0400] 937 Bytes | 263 tokens | Cum: 1570 tkns (19.62% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-17T16:09:00Z - Biomerica's Fortel Kidney Disease Test Approved In UAE For Early Detection Of CKD...
A2 - 2025-04-17T12:34:14Z - Biomerica's kidney disease test approved for UAE market By Investing.com...
A3 - 2025-04-17T12:33:13Z - Biomerica's kidney disease test approved for UAE market By Investing.com...
A4 - 2025-04-17T12:27:14Z - United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® Kidney Disease T...
A5 - 2025-04-17T12:34:14Z - Biomerica's kidney disease test approved for UAE market By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

BMRA_OUT_7 [2025-04-17 19:17:14 -0400] 1181 Bytes | 290 tokens | Cum: 1862 tkns (23.28% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**Biomerica's Fortel Kidney Disease Test Approved In UAE For Early Detection Of CKD**Date: 2025-04-17Source: {'uri': 'nasdaq.com', 'dataType': 'news', 'title': 'NASDAQ Stock Market'}URL: https://www.nasdaq.com/articles/biomericas-fortel-kidney-disease-test-approved-uae-early-detection-ckd(RTTNews) - Biomerica, Inc. (BMRA), Thursday announced that the United Arab Emirates Ministry of Health and Prevention has approved the Fortel Kidney Disease Test for commercial sale across the UAE.

The regulatory milestone enables the company to expand access to its 10-minute urine-based diagnostic for the early detection of kidney damage, particularly in high-risk populations.

The Fortel Kidney Disease Test detects microalbumin in urine, a key early marker of chronic kidney disease or CKD, which often progresses silently until advanced stages.

The test is especially relevant for individuals with

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BMRA_OUT_9 [2025-04-17 19:17:15 -0400] 1181 Bytes | 260 tokens | Cum: 2124 tkns (26.55% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): diabetes, hypertension, obesity, or those over age 65, all of whom face elevated CKD risk.

"With the high prevalence of diabetes and hypertension in the UAE, this approval supports our mission to bring life-saving diagnostic tools to communities where they are most needed," said Zack Irani, CEO of Biomerica.

CKD is a major global health concern projected to become the 5th leading cause of years of life lost by 2040, yet more than 80% of at-risk patients remain undiagnosed.

Early detection allows for timely intervention to delay disease progression and reduce the need for dialysis or transplantation, while also lowering healthcare costs.

The UAE approval further strengthens Biomerica's presence in the Middle East, following regional success with other products such as the EZ Detect Colon Disease Test.

The company is partnering with leading healthcare distributors to ensure broad ava

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BMRA_OUT_11 [2025-04-17 19:17:16 -0400] 701 Bytes | 171 tokens | Cum: 2297 tkns (28.71% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): ilability of the Fortel Kidney Disease Test across the UAE.

Biomerica continues to focus on delivering cost-effective, easy-to-use diagnostics to support early intervention and better health outcomes worldwide.

Currently, BMRA is trading at $0.46 up by 11.37 percent on the Nasdaq.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BMRA_OUT_13 [2025-04-17 19:17:17 -0400] 1025 Bytes | 327 tokens | Cum: 2626 tkns (32.82% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-16 8-K Item 7.01 Regulation FD Disclosure

On April 16, 2025, the Company issued a press release announcing the Reverse Stock Split, a copy of which is furnished as an exhibit to this report.

The information in this Item 7.01, including Exhibit 99.1 to this report, is being furnished...

S2 - 2025-04-14 10-Q PART I - FIN INFO

ITEM 1. FIN STATEMENTS

BIOMERICA, INC. & SUBSIDIARIES

COND CONS BAL SHEETS (UNAUDITED)

February 28, 2025 May 31, 2024 Assets Curr Assets: Cash and cash equiv $ 3,058,000 $ 4,170,000 A/R, net 1,...

S3 - 2025-01-14 10-Q PART I - FIN INFO

ITEM 1. FIN STATEMENTS

BIOMERICA, INC. & SUBSIDIARIES

COND CONS BAL SHEETS (UNAUDITED)

November 30, 2024 May 31, 2024 Assets Curr Assets: Cash and cash equiv $ 2,372,000 $ 4,170,000 A/R, ne...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

BMRA_OUT_15 [2025-04-17 19:17:18 -0400] 1181 Bytes | 286 tokens | Cum: 2914 tkns (36.43% of 8k)
==========================================================================

Showing S1 (chunk 1 of 3): S1:
Item 7.01 Regulation FD Disclosure

On April 16, 2025, the Company issued a press release announcing the Reverse Stock Split, a copy of which is furnished as an exhibit to this report.

The information in this Item 7.01, including Exhibit 99.1 to this report, is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to liability under that section or Section 11 and 12(a)(2) of the Securities Act of 1933, as amended (the Securities Act). The information contained in this Item 7.01 and Exhibit 99.1 shall not be incorporated by reference into any filing under the Exchange Act or the Securities Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Forward-Looking Statements

All statements in this press release th

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BMRA_OUT_17 [2025-04-17 19:17:21 -0400] 1181 Bytes | 256 tokens | Cum: 3172 tkns (39.65% of 8k)
==========================================================================

Showing S1 (chunk 2 of 3): at are not based on historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements may be identified by words such as will and expected, or the negative of such terms, or other comparable terminology, and include statements about the Reverse Stock Split and the impacts, if any, on the Companys common stock. Forward-Looking statements are statements that are not historical facts. Such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein due to many factors. These forward-looking statements and such risks, uncertainties and other factors speak only as of the date of this Current Report on Form 8-K, and the C

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BMRA_OUT_19 [2025-04-17 19:17:22 -0400] 632 Bytes | 145 tokens | Cum: 3319 tkns (41.49% of 8k)
==========================================================================

Showing S1 (chunk 3 of 3): ompany expressly disclaims any obligation or undertaking to update or revise and forward-looking statement contained herein, or to reflect any change in our expectations with regard thereto or any other change in events, conditions, or circumstances on which any such statement is based, except to the extent otherwise required by applicable law....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BMRA_OUT_21 [2025-04-17 19:17:28 -0400] 5850 Bytes | 1584 tokens | Cum: 4905 tkns (61.31% of 8k)
==========================================================================

This is our set of metrics for BIOMERICA.
Please analyze the numbers.

+-------------------+-----------------------+-------------------------+----------------------+
| Volume: 814,307 | Perf Month: -29.16% | Option/Short: Yes / Yes | Sales Y/Y TTM: 5.05% |
+-------------------+-----------------------+-------------------------+----------------------+
| Avg Volume: 1.04M | Perf Quarter: -32.00% | Short Float: 1.02% | ROE: -72.70% |
+-------------------+-----------------------+-------------------------+----------------------+
| Rel Volume: 0.79 | Index: - | Short Ratio: 0.18 | ROI: -84.69% |
+-------------------+-----------------------+-------------------------+----------------------+
| RSI (14): 41.17 | Market Cap: 9.78M | Short Interest: 0.19M | Sales Surprise: - |
+-------------------+-----------------------+-------------------------+----------------------+
| ATR (14): 0.07 | Shs Outstand: 20.37M | Beta: 0.45 | EPS Surprise: - |
+-------------------+-----------------------+-------------------------+----------------------+
| SMA20: -14.59% | Shs Float: 18.16M | Sales Q/Q: 10.03% | P/E: - |
+-------------------+-----------------------+-------------------------+----------------------+
| SMA50: -26.32% | Inst Own: 6.91% | Sales past 5Y: 25.62% | Earnings: - |
+-------------------+-----------------------+-------------------------+----------------------+
| SMA200: 9.88% | Insider Own: 10.82% | Employees: 64 | |
+-------------------+-----------------------+-------------------------+----------------------+
| Perf Week: -6.47% | Insider Trans: 0.00% | Debt/Eq: 0.10 | |
+-------------------+-----------------------+-------------------------+----------------------+

The next section covers any insider trading by BIOMERICA officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 1636000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -950000, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.4801
Average Volume: 205166.78
30-Day High: 0.7099
30-Day Low: 0.4201

[Detailed Financials: Q2 2025]
- Total Assets: $7,274,000.00
- Total Liabilities: $2,160,000.00
- Total Equity: $5,114,000.00
- Current Assets: $5,945,000.00
- Current Liabilities: $1,876,000.00

[Income Statement: Q2 2025]
- Revenue: $1,636,000.00
- Net Income: $-950,000.00
- Gross Profit: $437,000.00
- Operating Income: $-993,000.00
- Earnings Per Share (EPS): -0.06

[Cash Flow Statement: Q2 2025]
- Net Cash Flow: $1,344,000.00

[Detailed Financials: Q1 2025]
- Total Assets: $7,870,000.00
- Total Liabilities: $2,524,000.00
- Total Equity: $5,346,000.00
- Current Assets: $6,445,000.00
- Current Liabilities: $2,151,000.00

[Income Statement: Q1 2025]
- Revenue: $1,807,000.00
- Net Income: $-1,316,000.00
- Gross Profit: $289,000.00
- Operating Income: $-1,368,000.00
- Earnings Per Share (EPS): -0.08

[Cash Flow Statement: Q1 2025]
- Net Cash Flow: $-1,344,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of BIOMERICA (BMRA).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about BIOMERICA.

2) MARKET_SCORE[]
This conversation was initiated because BMRA is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for BMRA.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, BMRA could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect BMRA to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of BIOMERICA.

11) ETHICAL_RATING[]
Rate BIOMERICA’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of BIOMERICA.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

BMRA_IN_23 [2025-04-17 19:17:28 -0400] 126 Bytes | 29 tokens | Cum: 5131 tkns (64.14% of 8k)
==========================================================================

====================================
[2025-04-17 19:17:28] # Analysis Completed
Elapsed Time: 20.84 seconds